# A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

> **NCT06533059** · PHASE1 · RECRUITING · sponsor: **Alterome Therapeutics, Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Cancer
- Breast Cancer
- Endometrial Cancer
- Metastatic Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** ALTA2618

## Key facts

- **NCT ID:** NCT06533059
- **Lead sponsor:** Alterome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2026-12-29
- **Final completion:** 2027-12-29
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533059, "A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06533059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*